References
Budd, H. S.; O'Gorman, J.; Chiao, P. et al. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease, 4(4):255-263, 2017.
Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells – Salk Institute for Biological Studies. Published 2016.
Currais, A.; Quehenberger, O.; Armando, A. M.; Daugherty, D.; Maher, P. and Schubert, D. Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. npj Aging and Mechanisms of Disease (2016).
Fassler, M.; Rappaport, M. S.; Cuño, C. B. and George, J. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer’s disease models. Journal of Neuroinflammation, 18:19, 2021.
Gowran, A.; Noonan, J. and Campbell, V. A. The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neurosci. Ther. 17, 6, 637–644, 2011.
Heemels, M. T. Neurodegenerative diseases. Nature 539, 179, 2016.
Karelina, T.; Lerner, S.; Stepanov, A.; Meerson, M. and Demin, O. Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform. CPT: Pharmacometrics & Systems Pharmacology, 10, 8, 2021.
Nishibori, M.; Mori, S. and Takahashi, H. K. Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases. Journal of Pharmacological Sciences, 140, 1, 94-101, 2019.
Sauer, A. The Effects of Medical Marijuana on Alzheimer’s Treatment. Published 2016. Disponível na Internet: http://www.alzheimers.net/6-15-15-effects-of-medical-marijuana-on-alzheimers/.
Xing, H., Y.; Li, B.; Peng, D.; Wang, C. Y.; Wang, G. Y.; Li, P. et al. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer’s disease. PLoS ONE 12(6), 2017.
Watt, G.: Karl, T. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer’s disease. Front. Pharmacol. 8 (FEB):1–7, 2017.
The Use of Monoclonal Antibodies in Treatment of Alzheimer Disease Hemen Moradi-Sardareh1, Maryam Moradi2, Elham Bordbar3, Mohammadreza
Malekpour4, Sara Bagheri5, Nasrin Nakhodazadeh6, Shahin Rahbar7, Javad Farhadian Asgarabadi8, Meysam Ebrahimi Far9